secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107300
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Q2 net loss $42.1M, cash $211.7M; advances KYV-101 in SPS and MG
------------------------------------------------------------------------

- Net loss $42.1M ($0.97/share) vs $28.8M in Q2 2024; R&D expenses rose to $35.8M from $27.3M.
- Cash and equivalents $211.7M as of June 30, 2025, funding operations into 2027.
- Phase 2 SPS registrational trial enrollment complete; topline data and BLA filing expected 1H 2026.
- Phase 3 MG trial (~60 patients) enrollment to start by year-end 2025; interim Phase 2 data in Q4 2025.
- Marc Grasso appointed CFO in June 2025; KYV-102 IND filing expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/0000950170-25-107300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/kytx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer